These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23890208)

  • 1. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.
    Baldassarre M; Giannone FA; Napoli L; Tovoli A; Ricci CS; Tufoni M; Caraceni P
    Liver Int; 2013 Oct; 33(9):1298-308. PubMed ID: 23890208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the endocannabinoid system in liver diseases.
    Caraceni P; Domenicali M; Giannone F; Bernardi M
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoids and their role in fatty liver disease.
    Mallat A; Lotersztajn S
    Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
    Mallat A; Lotersztajn S
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G9-G12. PubMed ID: 17975129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
    Silvestri C; Di Marzo V
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research progress of role of cannabinoid receptor in fibrosis].
    Li S; Wang L; Liu M; Gao Y; Tian Z; Jiang S; Zhang M; Guan D
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):136-8. PubMed ID: 24742582
    [No Abstract]   [Full Text] [Related]  

  • 7. Cannabinoid signaling and liver therapeutics.
    Mallat A; Teixeira-Clerc F; Lotersztajn S
    J Hepatol; 2013 Oct; 59(4):891-6. PubMed ID: 23567085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
    Sulcová A
    Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endocannabinoid system and liver diseases.
    Caraceni P; Domenicali M; Bernardi M
    J Neuroendocrinol; 2008 May; 20 Suppl 1():47-52. PubMed ID: 18426499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
    Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis.
    Giannone FA; Baldassarre M; Domenicali M; Zaccherini G; Trevisani F; Bernardi M; Caraceni P
    Lab Invest; 2012 Mar; 92(3):384-95. PubMed ID: 22184091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoids as novel mediators of liver diseases.
    Mallat A; Lotersztajn S
    J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the endocannabinoid system in drug addiction.
    Manzanares J; Cabañero D; Puente N; García-Gutiérrez MS; Grandes P; Maldonado R
    Biochem Pharmacol; 2018 Nov; 157():108-121. PubMed ID: 30217570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis.
    Bazwinsky-Wutschke I; Zipprich A; Dehghani F
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31121839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
    Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.
    Tam J
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):267-76. PubMed ID: 26280171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cannabinoids in chronic liver diseases.
    Parfieniuk A; Flisiak R
    World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system and its role in the pathogenesis and treatment of cardiovascular disturbances in cirrhosis.
    Măries L; Manitiu I
    Acta Gastroenterol Belg; 2013 Jun; 76(2):195-9. PubMed ID: 23898556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis.
    Siegmund SV; Schwabe RF
    Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G357-62. PubMed ID: 18006606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.